SPARC has recently attracted substantial interest due to its roles in obesity, insulin resistance, and metabolic syndrome [77], and FGF21 is thought to have therapeutic potential for obesity, T2DM, and NAFLD [84]. This evidence concerns the gene FGF21 and metabolic syndrome.